^
    Back
    Association details:
    Biomarker:HRAS mutation
    Cancer:Salivary Gland Cancer
    Drug:Zarnestra (tipifarnib) (CXCL12 inhibitor, Farnesyl transferase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ACS Publications
    Title:

    Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer

    Published date:
    06/18/2020
    Excerpt:
    Tipifarnib resulted in modest clinical activity with a promising disease control rate among patients with HRAS ‐mutant, R/M SGC who developed disease progression within the last 6 months.
    DOI:
    https://doi.org/10.1002/cncr.3303
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Preliminary activity of tipifarnib in tumors of the head and neck, salivary gland and urothelial tract with HRAS mutations.

    Published date:
    05/13/2020
    Excerpt:
    We report data from two phase 2 clinical trials investigating the activity of tipifarnib in HRAS mutant (HRASm) solid tumors...In addition, 13 pts with recurrent/metastatic salivary gland tumors (SGT) were treated in KO-TIP-001 or in extended access programs. One objective response was observed in 12 (8%) evaluable pts and an additional 7 (58%) had stable disease as best response. Median PFS in SGT pts was 7 months.
    DOI:
    10.1200/JCO.2020.38.15_suppl.6504